Discovering and developing life-changing therapies to treat rare central nervous system (CNS) disorders

SAGE Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders.

Year Invested: 2011
Location: Cambridge, Mass.

Recent News

February 17, 2017
Sage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017

February 16, 2017
Sage Therapeutics Not in M&A Discussions: STATEMENT

February 13, 2017
Sage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder

Read More News

Associated Team Members

Kevin Starr